Literature DB >> 19546096

Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension.

T J Corte1, S J Wort, M A Gatzoulis, P Macdonald, D M Hansell, A U Wells.   

Abstract

BACKGROUND: Pulmonary hypertension (PH) is associated with a poor prognosis in diffuse lung disease (DLD). A study was undertaken to compare the prognostic significance of invasive and non-invasive parameters in patients with DLD and suspected PH.
METHODS: Hospital records of consecutive patients with DLD undergoing right heart catheterisation (RHC) were reviewed (n = 66). Mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR) and non-invasive variables were examined against early (within 12 months) and overall mortality. A priori thresholds were examined against early mortality. Relationships between mPAP, PVR and non-invasive markers were assessed.
RESULTS: Fifty patients had PH on RHC (mean (SD) mPAP 33.5 (11.8) mm Hg, PVR 5.9 (4.3) Wood units (WU)). Raised PVR was strongly associated with early mortality (odds ratio (OR) 1.30; 95% confidence interval (CI) 1.11 to 1.52; p = 0.001), with PVR > or = 6.23 WU being the optimal threshold after adjustment for age, gender, composite physiological index (CPI) and diagnosis of idiopathic pulmonary fibrosis (OR 11.09; 95% CI 2.54 to 48.36; p = 0.001). Early mortality was linked, albeit less strongly, to right ventricular dilation at echocardiography, but not to other non-invasive variables or mPAP. Overall mortality was most strongly associated with increasing CPI levels. Correlations between PVR and non-invasive variables were moderate (R(2) <0.32), improving little following construction of a multivariate index which did not itself predict mortality.
CONCLUSION: In severe DLD, early mortality is strongly linked to increased PVR but not to other RHC or non-invasive variables. These findings suggest that the threshold for RHC in severe DLD should be low, enabling prioritisation of aggressive treatment including lung transplantation.

Entities:  

Mesh:

Year:  2009        PMID: 19546096     DOI: 10.1136/thx.2008.112847

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  15 in total

1.  Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide.

Authors:  Lauren Rose; Kurt W Prins; Stephen L Archer; Marc Pritzker; E Kenneth Weir; Jeffrey R Misialek; Thenappan Thenappan
Journal:  J Heart Lung Transplant       Date:  2018-09-14       Impact factor: 10.247

2.  Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis.

Authors:  Likurgos Kolilekas; Effrosyni Manali; Katerina A Vlami; Panagiotis Lyberopoulos; Christina Triantafillidou; Konstantinos Kagouridis; Katerina Baou; Sotirios Gyftopoulos; Konstantinos N Vougas; Anna Karakatsani; Manos Alchanatis; Spyros Papiris
Journal:  J Clin Sleep Med       Date:  2013-06-15       Impact factor: 4.062

3.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

4.  Echocardiographic and hemodynamic predictors of mortality in idiopathic pulmonary fibrosis.

Authors:  Belinda N Rivera-Lebron; Paul R Forfia; Maryl Kreider; James C Lee; John H Holmes; Steven M Kawut
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

5.  Refractory pulmonary sarcoidosis - proposal of a definition and recommendations for the diagnostic and therapeutic approach.

Authors:  Peter Korsten; Katharina Strohmayer; Robert P Baughman; Nadera J Sweiss
Journal:  Clin Pulm Med       Date:  2016-03

6.  Non-invasive screening for pulmonary hypertension in idiopathic pulmonary fibrosis.

Authors:  Laith Alkukhun; Xiao-Feng Wang; Mostafa K Ahmed; Manfred Baumgartner; Marie M Budev; Raed A Dweik; Adriano R Tonelli
Journal:  Respir Med       Date:  2016-06-02       Impact factor: 3.415

Review 7.  Pulmonary vascular disease in the setting of heart failure with preserved ejection fraction.

Authors:  Andrea R Levine; Marc A Simon; Mark T Gladwin
Journal:  Trends Cardiovasc Med       Date:  2018-08-17       Impact factor: 6.677

8.  Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia.

Authors:  Tamera J Corte; Gregory J Keir; Konstantinos Dimopoulos; Luke Howard; Paul A Corris; Lisa Parfitt; Claire Foley; Monica Yanez-Lopez; Daphne Babalis; Philip Marino; Toby M Maher; Elizabeth A Renzoni; Lisa Spencer; Charlie A Elliot; Surinder S Birring; Katherine O'Reilly; Michael A Gatzoulis; Athol U Wells; Stephen J Wort
Journal:  Am J Respir Crit Care Med       Date:  2014-07-15       Impact factor: 21.405

Review 9.  Managing comorbidities in idiopathic pulmonary fibrosis.

Authors:  Blair G Fulton; Christopher J Ryerson
Journal:  Int J Gen Med       Date:  2015-09-22

10.  Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias.

Authors:  Marius M Hoeper; Juergen Behr; Matthias Held; Ekkehard Grunig; C Dario Vizza; Anton Vonk-Noordegraaf; Tobias J Lange; Martin Claussen; Christian Grohé; Hans Klose; Karen M Olsson; Thomas Zelniker; Claus Neurohr; Oliver Distler; Hubert Wirtz; Christian Opitz; Doerte Huscher; David Pittrow; J Simon R Gibbs
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.